利妥昔单抗在B细胞非霍奇金淋巴瘤中的应用进展(4)
[18] Milpied N，Deconinck E,Gaillard F，et al.Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stemcell support.New Engl J Med，2004，350(13):1287-1295.
[19] Naparstek E.The role of the anti-CD20antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin lymphoma.Curr Hematol Rep，2005，4(4):276-283.
[20] Hoerr Al ，Gao F，Hidalgo J，et al.Effects of pretransplantation treatment with rituximab on outcomes of autologous stem cell transplantation for non-Hodgkin’s lymphoma.J Clin Onco1，2004，22(22):4561-4566.
[21] Pfreundschuch M，Kloess M，Schmits R，et al.Six，not eight cycles of Bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL):results of the RICOVER-60 trial of the German High-grade Non-Hodgkin Lymphoma Study Group (DSHNHL)[abstract].Blood，2005，106:9a.
[22] Ghielmini M，Schmitz S-FH，Cogliatti SB，et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood，2004，103(12):4416-4423., http://www.100md.com(刘丽萍 冉学红 任翠爱)
[19] Naparstek E.The role of the anti-CD20antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin lymphoma.Curr Hematol Rep，2005，4(4):276-283.
[20] Hoerr Al ，Gao F，Hidalgo J，et al.Effects of pretransplantation treatment with rituximab on outcomes of autologous stem cell transplantation for non-Hodgkin’s lymphoma.J Clin Onco1，2004，22(22):4561-4566.
[21] Pfreundschuch M，Kloess M，Schmits R，et al.Six，not eight cycles of Bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL):results of the RICOVER-60 trial of the German High-grade Non-Hodgkin Lymphoma Study Group (DSHNHL)[abstract].Blood，2005，106:9a.
[22] Ghielmini M，Schmitz S-FH，Cogliatti SB，et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood，2004，103(12):4416-4423., http://www.100md.com(刘丽萍 冉学红 任翠爱)